FischerB., BryantJ., WolmarkN.: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol, 16: 2672–2685, 1998.
2.
BearH.D., AndersonS., BrownA.: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol, 21: 4165–4174, 2003.
3.
Von MinckwitzG., RaabM., SchietteJ.: Dose-dense versus sequential adriamicyn/docetaxel combination as preoperative chemotherapy (pCHT) in operable breast cancer (T2-3, N0-2,M0) primary endpoint analysis of the GEPARDUO study. Proc ASCO, 21: 168A, 2002.
4.
HutcheonA.W., HeysS.D., SarkarT.K.: Docetaxel primary chemotherapy in breast cancer: a five year update of the Aberdeen trial. SABCS, abst 11, 2003.
5.
CostaS., Von MinckwitzC., JackischC.: TAC as neoadjuvant chemotherapy in patients with primary breast cancer – interim progress report on 907 cases of the randomized prospective Gepartrio trial. Proc ASCO, 2004;23: 825A, 2004.
6.
No authors listed. Ovarian ablation for early breast cancer. Early Breast Cancer Trialists' Collaborative Group. Cochrane Database Syst Rev2000; 2: CD000485.
7.
No author listed. Polichemotherapy for early breast cancer: an overview of the randomized trials. Early Breast Cancer Trialists Collaborative Group. Lancet, 352: 930–942, 1998.
8.
HendersonI.C., BereryD.A., DemetriG.D.: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol, 21: 976–983, 2003.
9.
MamounasE.P., BryantJ., LemberskyB.C.: Paclitaxel following doxorubicin/cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer. Proc ASCO, 22: 12A, 2003.
10.
MartinM., PienkowskiT., MackeyJ.: TAC improves DFS and OS over FAC in node positive early breast-cancer patients, BCIRG001. SABCS, abst 43, 2003.
11.
MartinM., LluchA., SeguìA.: Prophylactic growth factor (GF) support with adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-negative breast cancer (BC): an interim safety analysis of the GEICAM 9805 study. Proc Am Soc Clin Oncol2004; 23: abst 620.
12.
CrownJ., DierasV., KaufamannM.: Chemotherapy for metastatic breast cancer: report of a European expert panel. Lancet Oncology, 3: 719–727, 2002.
